Senseonics (NYSE:SENS) Stock Price Down 5% – Here’s Why

Senseonics Holdings, Inc. (NYSE:SENS)’s stock price was down 5% during trading on Wednesday . The stock traded as low as $1.04 and last traded at $1.06. Approximately 4,024,237 shares changed hands during trading, a decline of 81% from the average daily volume of 21,064,957 shares. The stock had previously closed at $1.11.

Wall Street Analyst Weigh In

Several research firms have weighed in on SENS. StockNews.com began coverage on Senseonics in a research report on Thursday, December 26th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Price Performance

The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The company has a market capitalization of $619.14 million, a P/E ratio of -8.00 and a beta of 0.64. The firm’s 50-day moving average is $0.53 and its 200-day moving average is $0.43.

Senseonics (NYSE:SENS) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). The firm had revenue of $4.26 million for the quarter, compared to analysts’ expectations of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. Analysts predict that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Senseonics news, CFO Frederick T. Sullivan bought 124,933 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the transaction, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Timothy T. Goodnow acquired 315,000 shares of Senseonics stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the purchase, the chief executive officer now owns 11,310,355 shares in the company, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. Cubist Systematic Strategies LLC increased its position in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Symmetry Partners LLC acquired a new position in Senseonics during the third quarter worth $164,000. GSA Capital Partners LLP purchased a new position in shares of Senseonics in the 3rd quarter valued at about $117,000. FMR LLC boosted its stake in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after purchasing an additional 179,103 shares in the last quarter. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.